Table 1 : Clinical characteristics of study patients by CKD stage.

	All stages	Stage 3	Stage 4	Stage 5	p-value
Number of patients	120	40	40	40	--
Male/female	70:50	27:13	25:15	18:22	Ns
Age (yrs)(mean)	46.73±14.18	44.68±15.22	47.38±14.39	48.05±12.96	Ns
Duration of CKD(yrs)	2.98±1.47	2.25±1.19	3.23±1.49	3.48±1.46	<0.001
eGFR[mean] (ml/min/1.73m2)	24.16±12.17	39.21±16.48	21.30±3.75	11.98±1.73	<0.0001
Serum creatinine (mg/dl)[mean]	3.27±1.34	1.85±0.24	3.12±0.54	4.83±0.73	<0.0001
S.B.P.(mmHg)	135.60±11.80	135.38±12.24	135.05±11.52	136.38±11.90	Ns
D.B.P.( mmHg)	83.16±6.87	83.55±6.99	82.35±7.30	83.58±6.39	Ns
On any anti-hypertensive (%)	80.83%	72.5%	80%	90%	Ns
H/O CAD (%)	39.16%	32.5%	37.5%	47.5%	Ns
H/O Smoking(%)	31%	35%	30%	27.5%	Ns
Diabetes mellitus (%)	40%	37.5%	37.5%	45%	Ns
BSA (m2) [mean]	1.61±0.11	1.60±0.11	1.62±0.12	1.62±0.11	Ns
LVMI (g/m2)[mean]	134.92±21.71	126 ±   14.62	131.65±16.61	147.10±26.54	<0.0001
LVH;LVMI>125g/m2(%)	60%	55%	57.5%	67.5%	Ns
BMI (kg/m2)[mean]	22.68±2.48	22.20±2.01	22.99±2.85	22.84±2.50	Ns
Hemoglobulin (g/dl)	10.80±1.44	11.22±1.38	10.83±1.34	10.34±1.51	0.024
Intact PTH (pg/ml)	154.03±82.78	87.85±25.27	149.28±51.74	224.98±88.97	<0.0001
Ca x PO4 product (mg/dl)2	54.90±3.85	53.20±4.12	54.69±3.63	54.80±3.86	Ns
Serum cholesterol(mg/dl)	167.10±43.89	174.80±43.60	155.90±41.50	170.60±45.31	Ns
Patients on statins(%)	48.33%	42.5%	50%	52.5%	Ns
Plasma NT-proBNP(pg/ml)	585.68±514.84	350.30±277.34	613.35±561.51	793.40±560.98	<0.0001
Serum cTnT>.01,ng/ml (%)	40%	22.5%	37.5%	60%	0.002
Serum hs-CRP (mg/L)	5.96±2.52	5.91±2.68	5.94±2.62	5.99±2.31	Ns
Spot UACR(mg/g of creatinine)	719.37±411.36	394.58±261.43	740.43±366.39	1023.10±332.39	<0.0001

SBP: systolic blood pressure; DBP: diastolic blood pressure; H/O: history of; CAD: coronary artery disease;
BSA: body surface area; LVMI: left ventricular mass index; LVH: left ventricular hypertrophy; BMI: body mass index;
PTH: paratharmone; Ns: not significant